The FDA has announced that it will take the first steps to remove the indication for bevacizumab (Avastin) in metastatic breast cancer. Medscape Medical News
Three targeted therapies will not be covered by the National Heath Service for use in patients who progress after first-line chemotherapy. Medscape Medical News
Is a reduced-cycle chemotherapy plus lower-dose radiotherapy in patients with favorable stage I or II disease as effective as more standard regimens? Journal Watch